Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ALS lou gehrig's disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: ALS lou gehrig's disease. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2010-020010-28 Sponsor Protocol Number: EDTA Start Date*: 2010-09-22
    Sponsor Name:Dr.ssa Marina Aiello-Universit� degli studi di Parma
    Full Title: EVALUATION OF RESPIRATORY MUSCLES` FUNCTION IN PATIENTS AFFECTED BY ALS WITH HEAVY METAL POISONING
    Medical condition: PATIENTS AFFECTED BY ALS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005152-40 Sponsor Protocol Number: ALALS Start Date*: 2006-04-19
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
    Full Title: MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS
    Medical condition: ALS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002382-62 Sponsor Protocol Number: RNS60-ALS Start Date*: 2017-01-13
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: The effects of RNS60 on ALS biomarkers
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10052889 ALS LLT
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-004165-17 Sponsor Protocol Number: 2289/2007 Start Date*: 2007-09-25
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis.
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004459-21 Sponsor Protocol Number: Co-ALS Start Date*: 2018-09-11
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial
    Medical condition: Definite or probable amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    20.0 10029205 - Nervous system disorders 10052889 ALS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010060-41 Sponsor Protocol Number: 2707/2009 Start Date*: 2009-02-24
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Evaluation of efficacy of lithium salts therapy in patients with Amyotrophic Lateral Sclerosis.
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003248-75 Sponsor Protocol Number: STEMALS 01 Start Date*: 2005-08-31
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: PILOT STUDY ON SAFETY AND TOLERABILITY OF REPEATED MOBILIZATION PROCEDURES OF OSTEO-MEDULLARY DERIVED CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
    Medical condition: SLOWING OF ALS PROGRESSION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10002026 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007320-25 Sponsor Protocol Number: TRO19622 CL E Q 1015-1 Start Date*: 2009-06-24
    Sponsor Name:TROPHOS SA
    Full Title: Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with r...
    Medical condition: ALS is a fatal neuromuscular disorder causing progressive loss of nervous control of voluntary muscles because of destruction of motor neurons in the brain and spinal cord.Riluzole is the only appr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-003900-42 Sponsor Protocol Number: MT-1186-A04 Start Date*: 2022-07-15
    Sponsor Name:Mitsubishi Tanabe Pharma America, Inc. (MTPA)
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following S...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000376-38 Sponsor Protocol Number: MT-1186-A03 Start Date*: 2021-03-22
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc.
    Full Title: A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004842-40 Sponsor Protocol Number: IG1309 Start Date*: 2014-05-09
    Sponsor Name:Instituto Grifols S.A.
    Full Title: Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis
    Medical condition: Amytrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002099-15 Sponsor Protocol Number: APOCT-001 Start Date*: 2014-09-15
    Sponsor Name:Apodemus AB
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Amyotrophic lateral sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004619-30 Sponsor Protocol Number: ALXN1210-ALS-308 Start Date*: 2020-09-14
    Sponsor Name:Alexion Pharmaceuticals
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS), motor neuron disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004482-32 Sponsor Protocol Number: RAS-ALS Start Date*: 2013-04-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022818-19 Sponsor Protocol Number: 223AS302 Start Date*: 2011-03-22
    Sponsor Name:Biogen Idec Limited
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.
    Medical condition: amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) SE (Completed) IE (Completed) ES (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005611-31 Sponsor Protocol Number: CORT113176-652 Start Date*: 2022-09-07
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS)
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) ES (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000362-35 Sponsor Protocol Number: AMSC-ALS-001 Start Date*: 2012-03-29
    Sponsor Name:Bioinova, s.r.o.
    Full Title: A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis.
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005193-94 Sponsor Protocol Number: WVE-004-001 Start Date*: 2021-12-20
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Front...
    Medical condition: Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IE (Completed) SE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005347-14 Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 Start Date*: 2016-08-25
    Sponsor Name:CHU DE NIMES
    Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-004040-29 Sponsor Protocol Number: CY5031 Start Date*: Information not available in EudraCT
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS).
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IE (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) PL (Ongoing) IT (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 06:41:32 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA